Chen SJ - Search Results

1

Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial.

Jin J, Wang JX, Chen FF, Wu DP, Hu J, Zhou JF, Hu JD, Wang JM, Li JY, Huang XJ, Ma J, Ji CY, Xu XP, Yu K, Ren HY, Zhou YH, Tong Y, Lou YJ, Ni WM, Tong HY, Wang HF, Mi YC, Du X, Chen BA, Shen Y, Chen Z, Chen SJ. Jin J, et al. Among authors: chen ff, chen z, chen ba, chen sj. Lancet Oncol. 2013 Jun;14(7):599-608. doi: 10.1016/S1470-2045(13)70152-9. Epub 2013 May 9. Lancet Oncol. 2013. PMID: 23664707 Clinical Trial.

2

Expanding the use of arsenic trioxide: leukemias and beyond.

Chen Z, Chen GQ, Shen ZX, Sun GL, Tong JH, Wang ZY, Chen SJ. Chen Z, et al. Among authors: chen sj, chen gq. Semin Hematol. 2002 Apr;39(2 Suppl 1):22-6. doi: 10.1053/shem.2002.33611. Semin Hematol. 2002. PMID: 12012319 Review.

3

Treatment of acute promyelocytic leukemia with ATRA and As2O3: a model of molecular target-based cancer therapy.

Fang J, Chen SJ, Tong JH, Wang ZG, Chen GQ, Chen Z. Fang J, et al. Among authors: chen z, chen sj, chen gq. Cancer Biol Ther. 2002 Nov-Dec;1(6):614-20. doi: 10.4161/cbt.308. Cancer Biol Ther. 2002. PMID: 12642682 Review.

4

[Clinical observation of the short-term efficacy of the treatment with combination of all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) in newly diagnosed acute promyelocytic leukemia (APL)].

Liu YF, Shen ZX, Chen X, Wang AH, Cao Q, Zhu YM, Chen SJ, Chen Z, Wang ZY. Liu YF, et al. Among authors: chen z, chen sj, chen x. Zhonghua Xue Ye Xue Za Zhi. 2003 Jan;24(1):25-7. Zhonghua Xue Ye Xue Za Zhi. 2003. PMID: 12679006 Chinese.

5

Association between single nucleotide polymorphisms in deoxycytidine kinase and treatment response among acute myeloid leukaemia patients.

Shi JY, Shi ZZ, Zhang SJ, Zhu YM, Gu BW, Li G, Bai XT, Gao XD, Hu J, Jin W, Huang W, Chen Z, Chen SJ. Shi JY, et al. Among authors: chen z, chen sj. Pharmacogenetics. 2004 Nov;14(11):759-68. doi: 10.1097/00008571-200411000-00007. Pharmacogenetics. 2004. PMID: 15564883

6

Retinoic acid and arsenic for treating acute promyelocytic leukemia.

Zhou GB, Zhao WL, Wang ZY, Chen SJ, Chen Z. Zhou GB, et al. Among authors: chen z, chen sj. PLoS Med. 2005 Jan;2(1):e12. doi: 10.1371/journal.pmed.0020012. PLoS Med. 2005. PMID: 15696202 Free PMC article. Review.

7

Acute promyelocytic leukemia: a model of molecular target based therapy.

Zhou GB, Chen SJ, Chen Z. Zhou GB, et al. Among authors: chen z, chen sj. Hematology. 2005;10 Suppl 1:270-80. doi: 10.1080/10245330512331390519. Hematology. 2005. PMID: 16188687 Review.

8

Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.

Zhou GB, Zhang J, Wang ZY, Chen SJ, Chen Z. Zhou GB, et al. Among authors: chen z, chen sj. Philos Trans R Soc Lond B Biol Sci. 2007 Jun 29;362(1482):959-71. doi: 10.1098/rstb.2007.2026. Philos Trans R Soc Lond B Biol Sci. 2007. PMID: 17317642 Free PMC article. Review.

9

Back to the future of oridonin: again, compound from medicinal herb shows potent antileukemia efficacies in vitro and in vivo.

Zhou GB, Chen SJ, Wang ZY, Chen Z. Zhou GB, et al. Among authors: chen z, chen sj. Cell Res. 2007 Apr;17(4):274-6. doi: 10.1038/cr.2007.21. Cell Res. 2007. PMID: 17426700 No abstract available.

10

Mutant transcription factors and tyrosine kinases as therapeutic targets for leukemias: from acute promyelocytic leukemia to chronic myeloid leukemia and beyond.

Hu J, Zhou GB, Wang ZY, Chen SJ, Chen Z. Hu J, et al. Among authors: chen z, chen sj. Adv Cancer Res. 2007;98:191-220. doi: 10.1016/S0065-230X(06)98006-3. Adv Cancer Res. 2007. PMID: 17433911 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

3,104 results

Search Page